The trans fatty acid elaidate affects the global DNA methylation profile of cultured cells and in vivo
Lipids in Health and Diseasevolume 15, Article number: 75 (2016)
The deleterious effects of dietary trans fatty acids (tFAs) on human health are well documented. Although significantly reduced or banned in various countries, tFAs may trigger long-term responses that would represent a valid human health concern, particularly if tFAs alter the epigenome.
Based on these considerations, we asked whether the tFA elaidic acid (EA; tC18:1) has any effects on global DNA methylation and the transcriptome in cultured human THP-1 monocytes, and whether the progeny of EA-supplemented dams during either pregnancy or lactation in mice (n = 20 per group) show any epigenetic change after exposure.
EA induced a biphasic effect on global DNA methylation in THP-1 cells, i.e. hypermethylation in the 1–50 μM concentration range, followed by hypomethylation up to the 200 μM dose. On the other hand, the cis isomer oleic acid (OA), a fatty acid with documented beneficial effects on human health, exerted a distinct response, i.e. its effects were weaker and only partially overlapping with EA’s. The maximal differential response between EA and OA was observed at the 50 μM dose. Array expression data revealed that EA induced a pro-inflammatory and adipogenic transcriptional profile compared with OA, although with modest effects on selected (n = 9) gene promoter methylation. In mice, maternal EA supplementation in utero or via the breastmilk induced global adipose tissue DNA hypermethylation in the progeny, that was detectable postnatally at the age of 3 months.
We document that global DNA hypermethylation is a specific and consistent response to EA in cell culture and in mice, and that EA may exert long-term effects on the epigenome following maternal exposure.
Fatty acid (FA) trans isomers (tFAs) produced by fat hydrogenation in the food processing industry have been extensively linked to pathologies such as cardiovascular disease, diabetes and obesity . The pathogenic effects of tFAs have been attributed to biochemical alterations in cholesterol metabolism and structural changes in biomembranes, i.e. an increase in membrane rigidity due to the disruption of the ordered structure of the lipid bilayer . As a result, the legislation of several countries bans or limits the content of tFA in processed food, leading to a perceived lesser relevance for the topic of tFAs in human health (see: www.tfx.org.uk/page116.html for one of the earliest examples of tFA-banning laws). Yet, FA-rich lipoproteins and individual FAs including arachidonic, oleic and palmitic acid (AA, OA and PA, respectively) can modify the DNA methylome [3–5] (Silva-Martínez et al., in press), adding to a large number of other substances identified by nutritional epigenetics over the last decade [6, 7]. This body of evidence raises the question whether tFAs can modify the epigenome and therefore may exert long-term or transgenerational effects. To our knowledge, the effects of tFAs on DNA methylation have not been studied, besides the intriguing observation that the activity of the DNA methyltransferase inhibitor azacytidine is potentiated by esterification with the tFA elaidic acid (EA; tC18:1), suggesting that the latter may interact with chromatin .
To explore that issue, we asked whether EA modifies the DNA methylome and the transcriptome and whether such effects are distinct from the ones elicited by its cis isomer oleic acid (OA) in human THP-1 monocytes. We focused on EA and OA for their biological significance, as EA is one of the most abundant tFAs found in processed food and in circulation. Furthermore, OA has been attributed strikingly opposite, beneficial effects on human health compared to EA [9, 10], thus we assumed that differential epigenetic and transcriptional signatures between the two FAs were likely to be detectable. The rationale for using the THP-1 cell line as model is that it has been exploited to study the effects of lipoproteins and FAs on the DNA methylome ([3, 11] and our group’s unpublished data). In order to explore possible epigenetic long-term effects, we assessed whether EA shapes the DNA methylome in utero or during lactation in a mouse model. We discuss the results in the light of the current knowledge of FAs and disease risk.
Effects of EA and OA on global DNA methylation
We first explored the effects of EA and OA on global DNA methylation, i.e. total 5mdC content calculated by an HPLC-based technique - in THP-1 monocytes. FAs were used in the 1–200 μM concentration range. These values are within the physiological range . EA induced a biphasic effect on global DNA methylation, i.e. a hypermethylation in the 1–50 μM dose range corresponding to a 5.2 % increase in 5mdC levels, followed by a sharp hypomethylation up to the 200 μM dose (Fig. 1). On the other hand, OA exerted a similarly biphasic but weaker response peaking at 5 μM as previously reported (Silva-Martínez et al., in press). Furthermore, the response to OA did not significantly differ from the response induced by the carrier BSA up to the 50 μM dose. The maximal differential response between EA and OA was observed at 50 μM concentration.
Whole genome expression analysis of EA- and OA-stimulated THP-1 monocytes
In order to understand the impact of the OA- and EA-induced changes in DNA methylation on gene expression, we performed a global genome expression analysis using the Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array in THP-1 monocytes stimulated with 50 μM of either FA for 24 h. The rationale for using that FA concentration was that it corresponded to the maximal differential response between EA and OA in the global DNA methylation assay (see Fig. 1). The effects of 50 μM OA on global DNA methylation were not significantly different from the ones of BSA alone, therefore we only included EA- and OA-treated samples in the microarray analysis. Another reason for not including BSA-treated samples, is that because of the ubiquitous and continuous presence of FAs in the circulation, cultured cells not exposed to any FA do not have any physiological counterpart. A total of 137 probes corresponding to 100 annotated genes met the differential expression criteria of >2-fold absolute expression difference and p < 0.05 (t-test) (Additional file 1: Table S1). The majority (66 or 63.5 %) of the differentially expressed probes corresponding to annotated genes (104 probes, counting genes represented more than once) were down-regulated by EA. Expression datasets for the differentially expressed probes clearly clustered by FA treatment (Fig. 2). The functional enrichment analysis showed sharply distinct functions between genes up-regulated or down-regulated by EA (FDR < 0.05). The former were enriched in lipid biosynthesis activities, whereas the down-regulated genes were involved in cell cycle regulation (Table 1). A list of the EA-regulated genes belonging to those two functional categories and a summary of their function is shown in Additional file 1: Table S2. Other notable genes up-regulated by EA were pro-inflammatory factors (IL20RB, IL21R, SLAMF7), the cholesterol transporter ABCA1, chemokines (CCL2, CCL4, CCL8, IL8). Up-regulated genes were not significantly enriched for any transcription factor (TF) target category, but the down-regulated counterpart included targets for a number of TFs including interferon regulatory factor 2 (IRF2; FDR = 6.6 × 10−7). Among IRF2 targets were the inhibitors of inflammation myocyte enhancer factor 2C (MEF2C) and annexin A1, (ANXA1, also known as lipocortin 1), which was recently shown to decrease atherosclerosis in a mouse model [13–15]. The expression of a total of 11 genes was validated by reverse transcription-PCR (RT-PCR). Chemokines, inflammation-related and lipid metabolism-related genes including ANXA1, CCL4 and ADFP were among the successfully validated differentially expressed probes (Additional file 2: Figure S1). Next, we asked whether any change in promoter DNA methylation was associated with differential gene expression between EA- and OA-stimulated cells. We profiled DNA methylation in the promoters of 7 of the genes for which expression was validated, by direct sequencing of bisulfite-modified genomic DNA. In addition to the CpG dinucleotide context, where methylated cytosines are predominantly found mammals, we analyzed by methylation of cytosines located in the 5′ position of trinucleotides with guanosine or any nucleotide at the 3′ position - i.e. CHG or CHH, where H represents non-G nucleotides (A, T or C). CHG and CHH methylation, although present at low frequency, has been detected in specific cell types and in atherosclerosis in humans, and may have regulatory functions [16, 17]. Our results showed only weak, non-significant changes between EA- and OA-stimulated cells in any of three contexts analyzed. DNA methylation profiling of API5 and PDK4 promoters are shown as examples in Additional file 2: Figure S2.
Effects of EA on DNA methylation in the adipose tissue in mice
The above data indicated that EA exerts global DNA hypermethylation. To further corroborate those observations, we analyzed global DNA methylation in the progeny of dams supplemented with EA either during the whole pregnancy or lactation. The EA dose was 0.63 mg/day (0.7 μl) or the 30 g-body weight (BW) mouse equivalent of the tFA exposure of a 70 kg-human eating one generic cheeseburger every 3 days, which is slightly below recently calculated U.S.A. figures of 3 hamburgers/week (http://www.economist.com/node/154515?story_id=154515). EA did not have any significant effects on dam’s BW during pregnancy nor during lactation (n = 5 in each group). No adverse effects or macroscopic anatomical abnormalities were observed, with the exception of one case of fat necrosis in the mammary gland of one dam that had received EA during lactation.
The progeny however, showed a significant decrease in BW gain between birth and weaning that was significant only in males. BW gain, calculated as percent change compared to BW at birth, decreased by 16.6 ± 1.7 % and 10.1 ± 0.9 % in the male progeny of dams supplemented with EA during pregnancy or lactation, respectively, compared to controls (n = 10 for either sex in either treatment; p < 0.05 in both cases, Scheffé’s post hoc test). Global DNA methylation was measured in the progeny’s abdominal adipose tissue at 3 months of age. The rationale for choosing the adipose tissue was that EA alters the adipocyte’s fat composition and physiology . Data were obtained for 3 DNA pools in each of the 4 experimental groups, each pool corresponding to one litter. EA supplementation during either pregnancy or lactation caused a significant increase in DNA methylation (7.8 % and 14.4 %, respectively, p < 0.05, Mann–Whitney U test; MethylFlash assay) (Fig. 3).
We show that EA and OA exert distinct effects on global DNA methylation in human THP-1 monocytes. These global epigenome responses coincide with distinct whole transcriptome profiles, but are not matched by any difference in the promoter DNA methylation of any of the transcriptionally regulated genes tested. Our data suggest that EA may target mainly either gene-body or intergenic regulatory element DNA methylation. Accordingly, we recently showed that AA hypermethylates the gene-body of target genes and members of the ALU repeated family in the same THP-1 cell line used here (Silva-Martínez et al., in press). At any rate, we show that maternal EA supplementation during pregnancy or lactation induces changes in the progeny’s adipose tissue DNA methylation that are co-directional - i.e. hypermethylation in both cases - with the response to physiological doses of EA observed in THP-1 cells.
The transcriptional profile induced by EA in THP-1 cells is markedly adipogenic compared to OA, in accordance with published data obtained with EA or trans conjugated FAs [19, 20]. tFA-induced adipogenesis is accompanied by hepatic steatosis [19, 21–24], which may share underlying mechanisms with the fatty lesions observed here in one mammary gland of EA-treated dams. The marked adipogenic response to EA is not reflected in a BW gain. In fact, a sexually dimorphic, male-restricted decrease in BW was observed in the progeny of EA-treated dams. Our data are consistent with previous findings in models of prenatal and adult exposure [18, 25, 26], although contrasting results have been reported, showing no significant effect on BW [27, 28] or an increase in primates and rodents [29–31] and an association with obesity in humans . Despite these inconsistencies, our data suggest that the exposure to EA in utero or during lactation slows growth in the birth-to-weaning period. Males are more vulnerable to adverse maternal factors than females, and various mechanisms have been proposed for this sex-specific response, including functional differences in the immune system (extensively reviewed in ). Our results do not allow to conclude whether these effects are due to differential immunity, increased catabolism or decreased appetite. In addition, based on the enrichment of cell cycle-related genes in the transcripts down-regulated by EA in THP-1 monocytes, it is conceivable that the reduced BW gain in males may be due at least in part to reduced cell proliferation. Interestingly, the observation that the effects of EA on BW tended to be more marked following supplementation during pregnancy compared to supplmentation through breastmilk, suggested a developmental stage-related differential vulnerability to EA that deserves further research. At any rate, the low postnatal growth is interesting from a clinical viewpoint, as it may contribute to understand the association between EA intake and increased cardiovascular risk [33–36].
Our results in THP-1 monocytes identify specific responses to EA compared to other FAs. We recently identified the genes involved in the G protein-coupled receptor signalling pathway as a major targets in the transcriptional regulation by AA and OA, whereas EA did not modulate that pathway, nor AA or OA modulated the lipid biosynthesis pathway (Silva-Martínez et al., in press). In the same study, we showed by comparative genomics that PA induces differential DNA methylation in genes belonging to that same pathway. These genomic responses single out EA as a biologically peculiar FA when compared to AA, OA and PA, in line with the extensive evidence linking specifically tFAs to human disease.
We document that the tFA EA and its cis isomer OA exert distinct global DNA methylation and transcriptome profiles in cultured human cells. In addition, EA induces global changes in the adipose tissue DNA methylome that can be imposed by maternal exposure and are detectable postnatally for up to 3 months in a mouse model. Our data suggest that the deleterious effects of tFAs on human health may extend beyond any decrease in exposure due to legal control or voluntary abstention. However, further studies are required in order to identify the genes involved in EA-induced changes in the DNA methylome.
Cell culture and stimulation with FAs
THP-1 monocytes were cultured in RPMI-1640 medium (Gibco) supplemented with 2 mM L-Glutamine (Sigma), 10 % foetal calf serum (Gibco) and 1 % Penicillin/Streptomycin (Gibco). Cells were never allowed to grow above a 1–1.5 × 106 cells/ml concentration. Pure FAs (Sigma) were conjugated with cell culture-grade FA-free BSA (fraction V, FA-free, Sigma no. 820022) to achieve a FA:BSA 6:1 ratio, essentially as described . Typically, 5-6 × 106 cells in 10 ml medium were stimulated with 100x BSA-FA mix in 2 % FCS. Exclusion of trypan blue was used as a criterion for viability.
Female C57BL/6 mice were assigned to each of the following 4 groups, n = 5 per group. 1) Supplemented with 0.7 μl EA dissolved in 5 μl commercial soybean oil vehicle (Nutrioli brand) orally once a day for the whole pregnancy period, i.e. from the detection of the vaginal plug to the day prior to delivery (20 days). 2) As in the previous group but supplemented with vehicle alone. 3) Supplemented with EA as in the first group but during the entire lactation, i.e. between birth and weaning (28 d post partum). 4) As in group 3 but with vehicle alone. Due to the small volume, a micropipette was carefully used for oral administrations and mice were extensively monitored for any sign of discomfort and to ensure complete swallowing. At the age of 3 months, a total of 20 progeny mice - 10 for each sex - were randomly chosen from 3 of the most numerous litters, 8–6 siblings/litter, and dissected to obtain the epididymal fat pad for the downstream analyses. The choice of the three most numerous litter aimed at minimizing a possible effect of litter size. The post-exposure time at dissection was therefore 3 months and ~2 months for the pregnancy and lactation supplementation groups, respectively. The procedure was approved by the Ethical Committee of the Department of Medical Sciences of the University of Guanajuato.
Whole-genome expression data were obtained with the Affymetrix GeneChip Human Genome U133 Plus 2.0. Arrays were hybridized with labelled total RNA extracted by using the RNeasy system (Qiagen), scanned with an Affymetrix GeneChip Scanner 3000 according to standard protocols at the microarray facility, Rigshospitalet, Copenhagen, Denmark. RNA integrity was checked by agarose electrophoresis at the source laboratory and again at the microarray facility. The dChip software (build April 15, 2005) was used for normalization and modelling using the PM-only model. Clustering was performed with dChip. Expression microarray data are publicly available in the GEO database with accession number GSE74874. Validation was performed by RT-PCR using primers designed with the qPrimerDepot tool (primerdepot.nci.nih.gov). The primers listed in Additional file 1: Table S3.
DNA methylation analysis
DNA was extracted from cultured cells by standard methods (DNeasy system, Qiagen). Global DNA methylation was measured in THP-1 cells by a HPLC-based method yielding 5-methyl-2′-deoxycytidine (5mdC) values normalized by 2′-deoxyguanosine (dG) . Global DNA methylation in mice was measured by the MethylFlash system (Epigentek) according to the manufacturer’s instructions, using DNA extracted from one randomly chosen fragment of epididymal fat pad in each animal. The assay output is the percent 5-methyl-2′-deoxycytidine (5mdC) of PicoGreen-quantified input genomic DNA (wt/wt). The difference in the DNA methylation levels obtained with the two assays is therefore explained by the distinct normalization methods. Gene promoter DNA methylation profiling was carried out by sequencing at least 10 clones per FA treatment obtained by PCR amplification of bisulfite-treated genomic DNA. Primers were designed using the BiSearch tool (http://bisearch.enzim.hu) . Primer sequences are listed in Additional file 1: Table S3.
Comparisons were carried out by the Mann–Whitney U test. The only exception was the expression array data, where we used the t-test. The Kruskal-Wallis test followed by the Scheffé’s ANOVA post hoc test were applied to compare control and treated male and female mouse data. All tests were performed with the STATISTICA (StatSoft) software.
Chajès V, Biessy C, Ferrari P, Romieu I, Freisling H, Huybrechts I, Scalbert A, Bueno de Mesquita B, Romaguera D, Gunter MJ, Vineis P, Hansen CP, Jakobsen MU, Clavel-Chapelon F, Fagherazzi G, Boutron-Ruault M-C, Katzke V, Neamat-Allah J, Boeing H, Bachlechner U, Trichopoulou A, Naska A, Orfanos P, Pala V, Masala G, Mattiello A, Skeie G, Weiderpass E, Agudo A, Huerta JM, et al. Plasma elaidic acid level as biomarker of industrial trans fatty acids and risk of weight change: report from the EPIC study. PLoS One. 2015;10:e0118206.
Vendel Nielsen L, Krogager TP, Young C, Ferreri C, Chatgilialoglu C, Nørregaard Jensen O, Enghild JJ. Effects of elaidic acid on lipid metabolism in HepG2 cells, investigated by an integrated approach of lipidomics, transcriptomics and proteomics. PLoS One. 2013;8:e74283.
Rangel-Salazar R, Wickström-Lindholm M, Aguilar-Salinas CA, Alvarado-Caudillo Y, Døssing KBV, Esteller M, Labourier E, Lund G, Nielsen FC, Rodríguez-Ríos D, Solís-Martínez MO, Wrobel K, Wrobel K, Zaina S. Human native lipoprotein-induced de novo DNA methylation is associated with repression of inflammatory genes in THP-1 macrophages. BMC Genomics. 2011;12:582.
Hall E, Volkov P, Dayeh T, Bacos K, Rönn T, Nitert MD, Ling C. Effects of palmitate on genome-wide mRNA expression and DNA methylation patterns in human pancreatic islets. BMC Med. 2014;12:103.
Burdge GC, Lillycrop KA. Fatty acids and epigenetics. Curr Opin Clin Nutr Metab Care. 2014;17:156–61.
Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol. 2003;23:5293–300.
Ho E, Beaver LM, Williams DE, Dashwood RH. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr. 2011;2:497–510.
Brueckner B, Rius M, Markelova MR, Fichtner I, Hals P-A, Sandvold ML, Lyko F. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther. 2010;9:1256–64.
Brown WV. Dietary recommendations to prevent coronary heart disease. Ann N Y Acad Sci. 1990;598:376–88.
Huth PJ, Fulgoni 3rd VL, Larson BT. A Systematic Review of High-Oleic Vegetable Oil Substitutions for Other Fats and Oils on Cardiovascular Disease Risk Factors: Implications for Novel High-Oleic Soybean Oils. Adv Nutr. 2015;6:674–93.
Lund G, Andersson L, Lauria M, Lindholm M, Fraga MF, Villar-Garea A, Ballestar E, Esteller M, Zaina S. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004;279:29147–54.
Higashiyama A, Kubota Y, Marumo M, Konishi M, Yamashita Y, Nishimura K, Fukuda Y, Okamura T, Wakabayashi I. Association between serum long-chain n-3 and n-6 polyunsaturated fatty acid profiles and glomerular filtration rate assessed by serum creatinine and cystatin C levels in Japanese community-dwellers. J Epidemiol. 2015;25:303–11.
Xu Z, Yoshida T, Wu L, Maiti D, Cebotaru L, Duh EJ. Transcription Factor MEF2C Suppresses Endothelial Cell Inflammation via Regulation of NF-κB and KLF2. J Cell Physiol. 2015;230:1310–20.
Cirino G, Flower RJ, Browning JL, Sinclair LK, Pepinsky RB. Recombinant human lipocortin 1 inhibits thromboxane release from guinea-pig isolated perfused lung. Nature. 1987;328:270–2.
Kusters DH, Chatrou ML, Willems BA, De Saint-Hubert M, Bauwens M, van der Vorst E, Bena S, Biessen EAL, Perretti M, Schurgers LJ, Reutelingsperger CP. Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR−/− Mice on Western Type Diet. PLoS One. 2015;10:e0130484.
Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo Q-M, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315–22.
Zaina S, Heyn H, Carmona FJ, Varol N, Sayols S, Condom E, Ramírez-Ruz J, Gomez A, Gonçalves I, Moran S, Esteller M. DNA methylation map of human atherosclerosis. Circ Cardiovasc Genet. 2014;7:692–700.
Atal S, Zarnowski MJ, Cushman SW, Sampugna J. Comparison of body weight and adipose tissue in male C57Bl/6J mice fed diets with and without trans fatty acids. Lipids. 1994;29:319–25.
Collison KS, Maqbool Z, Saleh SM, Inglis A, Makhoul NJ, Bakheet R, Al-Johi M, Al-Rabiah R, Zaidi MZ, Al-Mohanna FA. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J Lipid Res. 2009;50:1521–37.
Murphy EF, Hooiveld GJ, Müller M, Calogero RA, Cashman KD. The effect of trans-10, cis-12 conjugated linoleic acid on gene expression profiles related to lipid metabolism in human intestinal-like Caco-2 cells. Genes Nutr. 2009;4:103–12.
Clément L, Poirier H, Niot I, Bocher V, Guerre-Millo M, Krief S, Staels B, Besnard P. Dietary trans-10, cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. J Lipid Res. 2002;43:1400–9.
Degrace P, Demizieux L, Gresti J, Chardigny J-M, Sébédio J-L, Clouet P. Association of liver steatosis with lipid oversecretion and hypotriglyceridaemia in C57BL/6j mice fed trans-10, cis-12-linoleic acid. FEBS Lett. 2003;546:335–9.
Machado RM, Stefano JT, Oliveira CP, Mello ES, Ferreira FD, Nunes VS, de Lima VM, Quintão EC, Catanozi S, Nakandakare ER, Lottenberg AM. Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr. 2010;140:1127–32.
Obara N, Fukushima K, Ueno Y, Wakui Y, Kimura O, Tamai K, Kakazu E, Inoue J, Kondo Y, Ogawa N, Sato K, Tsuduki T, Ishida K, Shimosegawa T. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol. 2010;53:326–34.
Kavanagh K, Sajadian S, Jenkins KA, Wilson MD, Carr JJ, Wagner JD, Rudel LL. Neonatal and fetal exposure to trans-fatty acids retards early growth and adiposity while adversely affecting glucose in mice. Nutr Res. 2010;30:418–26.
Loor JJ, Lin X, Herbein JH. Effects of dietary cis 9, trans 11–18:2, trans 10, cis 12–18:2, or vaccenic acid (trans 11–18:1) during lactation on body composition, tissue fatty acid profiles, and litter growth in mice. Br J Nutr. 2003;90:1039–48.
Marques TM, Wall R, O’Sullivan O, Fitzgerald GF, Shanahan F, Quigley EM, Cotter PD, Cryan JF, Dinan TG, Ross RP, Stanton C. Dietary trans-10, cis-12-conjugated linoleic acid alters fatty acid metabolism and microbiota composition in mice. Br J Nutr. 2015;113:728–38.
Liou J, Tuazon MA, Burdzy A, Henderson GC. Moderate Compared to Low Dietary Intake of trans-Fatty Acids Impairs Strength of Old and Aerobic Capacity of Young SAMP8 Mice in Both Sexes. Lipids. 2013;48:1135–43.
Kavanagh K, Jones KL, Sawyer J, Kelley K, Carr JJ, Wagner JD, Rudel LL. Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity (Silver Spring). 2007;15:1675–84.
Pimentel GD, Lira FS, Rosa JC, Oliveira JL, Losinskas-Hachul AC, Souza GI, das Graças T do Carmo M, Santos R V, de Mello MT, Tufik S, Seelaender M, Oyama LM, Oller do Nascimento CM, Watanabe RH, Ribeiro EB, Pisani LP. Intake of trans fatty acids during gestation and lactation leads to hypothalamic inflammation via TLR4/NFκBp65 signaling in adult offspring. J Nutr Biochem. 2012;23:265–71.
Collison KS, Zaidi MZ, Maqbool Z, Saleh SM, Inglis A, Makhoul NJ, Bakheet R, Al-Johi M, Al-Rabiah R, Zaidi MZ, Al-Mohanna FA. Sex-dimorphism in cardiac nutrigenomics: effect of trans fat and/or monosodium glutamate consumption. BMC Genomics. 2011;12:555.
Bolton JL, Bilbo SD. Developmental programming of brain and behavior by perinatal diet: focus on inflammatory mechanisms. Dialogues Clin Neurosci. 2014;16:307–20.
Eriksson JG, Forsén TJ, Kajantie E, Osmond C, Barker DJ. Childhood growth and hypertension in later life. Hypertension. 2007;49:1415–21.
Barker DJ, Osmond C, Kajantie E, Eriksson JG. Growth and chronic disease: findings in the Helsinki Birth Cohort. Ann Hum Biol. 2009;36:445–58.
Katan MB, Zock PL, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. Annu Rev Nutr. 1995;15:473–93.
Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med. 1999;340:1933–40.
Marshall C, Hitman GA, Cassell PG, Turner MD. Effect of glucolipotoxicity and rosiglitazone upon insulin secretion. Biochem Biophys Res Commun. 2007;356:756–62.
Magaña AA, Wrobel K, Caudillo YA, Zaina S, Lund G, Wrobel K. High-performance liquid chromatography determination of 5-methyl-2′-deoxycytidine, 2′-deoxycytidine, and other deoxynucleosides and nucleosides in DNA digests. Anal Biochem. 2008;374:378–85.
Tusnády GE, Simon I, Váradi A, Arányi T. BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res. 2005;33:e9.
We thank the Mexican Federal Council for Research and Technology (CONACyT; Basic Science (Ciencia Básica) grant no. 83401 to G.L.) and the Council for Research and Technology of the state of Guanajuato, Mexico (CONCyTEG; grant no. 08-03-K662-020-A01 to G.L.) for the generous support. J.d.J.F.-S., M.A.-G. and B.C.-P. were supported by CONACyT Studentships.
The authors declare that they have no competing interests.
JF-S performed mouse breeding, EA supplementation and phenotype analysis. MA-G performed cell culture and stimulation with FAs. BC-P and DR-R extracted DNA and RNA, and analyzed gene-specific expression and methylation. YA-C coordinated the cell culture work. FC-N performed expression array work from RNA QC to data normalization. SZ performed part of the DNA methylation analysis, participated in designing the study and writing the manuscript. KW and KW performed the HPLC-based DNA methylation assay. GL designed and supervised the study, and wrote the final manuscript draft. All authors read and approved the final manuscript.
Differentially expressed probes between EA and OA stimulated cells. Table S2. Genes differentially expressed in EA and OA stimulated cells for the significantly enriched functional gene categories listed in main text Table 1. Table S3. Primers used in RT-PCR and bisulfite-modified DNA sequencing. (PDF 134 kb)
Validation of selected expression array data for FA-stimulated THP-1 cells. RT-PCR results are shown for the indicated genes, performed in triplicate. Figure S2. Context-specific DNA methylation profiling of API5 and PDK4 promoters. Contexts (CG, CHG and CHH, where H indicates a non-G nucleotide - i.e. A, C or T. Open bars: OA. Solid bars: EA. (PPTX 1043 kb)